PET tracers based on zirconium-89

Current Radiopharmaceuticals

Volumn 4, Issue 2, 2011, Pages 131-139

  Zhang, Yin ^a   Hong, Hao ^a   Cai, Weibo ^a,b  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b UNIVERSITY OF WISCONSIN   (United States)

Author keywords

Cancer; Molecular imaging; Monoclonal antibody (mAb); Positron emission tomography (PET); RadioimmunoPET; Zirconium 89 (89zr)

Indexed keywords

BEVACIZUMAB; CARBONATE DEHYDRATASE IX; CD44V6 ANTIGEN; CETUXIMAB; CHELATING AGENT; DEFEROXAMINE; EPIDERMAL GROWTH FACTOR; GROWTH FACTOR RECEPTOR; PROSTATE SPECIFIC MEMBRANE ANTIGEN; SINGLE WALLED NANOTUBE; SOMATOMEDIN RECEPTOR; TRASTUZUMAB; UNCLASSIFIED DRUG; ZIRCONIUM 89; ZIRCONIUM DERIVATIVE;

ANGIOGENESIS; BREAST CANCER; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SURVIVAL; CHELATION; HUMAN; IMAGE ANALYSIS; IMMUNOREACTIVITY; ISOTOPE LABELING; METASTASIS; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIOCHEMISTRY; REVIEW;

ANIMALS; ANTIGENS, CD44; ANTIGENS, SURFACE; GLUTAMATE CARBOXYPEPTIDASE II; HUMANS; ISOTOPE LABELING; POSITRON-EMISSION TOMOGRAPHY; RADIOISOTOPES; RADIOPHARMACEUTICALS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; VASCULAR ENDOTHELIAL GROWTH FACTOR A; ZIRCONIUM;

EID: 79958265709     PISSN: 18744710     EISSN: 18744729     Source Type: Journal    
DOI: 10.2174/1874471011104020131     Document Type: Review

References (65)

1. Goldenberg, D.M.; Sharkey, R.M. Advances in cancer therapy with radiolabeled monoclonal antibodies. Q. J. Nucl. Med. Mol. Imaging, 2006, 50, 248-264.
2. Goldenberg, D.M.; Sharkey, R.M. Novel radiolabeled antibody conjugates. Oncogene, 2007, 26, 3734-3744.
3. McCardle, R.J.; Harper, P.V.; Spar, I.L.; Bale, W.F.; Andros, G.; Jiminez, F. Studies with iodine-131-labeled antibody to human fibrinogen for diagnosis and therapy of tumors. J. Nucl. Med., 1966, 7, 837-847.
4. Nayak, T.K.; Brechbiel, M.W. Radioimmunoimaging with longerlived positron-emitting radionuclides: potentials and challenges. Bioconjug. Chem., 2009, 20, 825-841.
5. Koehler, L.; Gagnon, K.; McQuarrie, S.; Wuest, F. Iodine-124: a promising positron emitter for organic PET chemistry. Molecules, 2010, 15, 2686-2718.
6. Lee, F.T.; Scott, A.M. Immuno-PET for tumor targeting. J. Nucl. Med., 2003, 44, 1282-1283.
7. Tang, L. Radionuclide production and yields at Washington University School of Medicine. Q. J. Nucl. Med. Mol. Imaging, 2008, 52, 121-133.
8. Lewis, J.S.; Welch, M.J.; Tang, L. Workshop on the production, application and clinical translation of "non-standard" PET nuclides: a meeting report. Q. J. Nucl. Med. Mol. Imaging, 2008, 52, 101-106.
9. 89Zr-labeled monoclonal antibodies. J. Nucl. Med., 2003, 44, 1271-1281.
10. Pagani, M.; Stone-Elander, S.; Larsson, S.A. Alternative positron emission tomography with non-conventional positron emitters: effects of their physical properties on image quality and potential clinical applications. Eur. J. Nucl. Med., 1997, 24, 1301-1327.
11. Dejesus, O.T.; Nickles, R.J. Production and purification of 89Zr, a potential PET antibody label. Int. J. Radiat. Appl. Instrum., A, Appl. Radiat. Isot., 1990, 41, 789-790.
12. Zweit, J.; Downey, S.; Sharma, H.L. Production of no-carrieradded zirconium-89 for positron emission tomography. Int. J. Radiat. Appl. Instrum., A, Appl. Radiat. Isot., 1991, 42, 199-201.
13. Holland, J.P.; Sheh, Y.; Lewis, J.S. Standardized methods for the production of high specific-activity zirconium-89. Nucl. Med. Biol., 2009, 36, 729-739.
14. Meijs, W.E.; Herscheid, J.D.M.; Haisma, H.J.; Pinedo, H.M. valuation of desferal as a bifunctional chelating agent for labeling antibodies with Zr-89. Int. J. Radiat. Appl. Instrum., A, Appl. Radiat. Isot., 1992, 43, 1443-1447.
15. Herscheid, J.D.; Hoekstra, A.; Vos, C.M. NSuccinyldesferrioxamine B: a potential radiopharmaceutical for assessing renal function. Eur. J. Nucl. Med., 1984, 9, 508-510.
16. Borjesson, P.K.; Jauw, Y.W.; Boellaard, R.; de Bree, R.; Comans, E.F.; Roos, J.C.; Castelijns, J.A.; Vosjan, M.J.; Kummer, J.A.; Leemans, C.R.; Lammertsma, A.A.; van Dongen, G.A. Performance of immuno-positron emission tomography with zirconium-89-labeled chimeric monoclonal antibody U36 in the detection of lymph node metastases in head and neck cancer patients. Clin. Cancer Res., 2006, 12, 2133-2140.
17. Perk, L.R.; Vosjan, M.J.; Visser, G.W.; Budde, M.; Jurek, P.; Kiefer, G.E.; van Dongen, G.A. p-Isothiocyanatobenzyldesferrioxamine: a new bifunctional chelate for facile radiolabeling of monoclonal antibodies with zirconium-89 for immuno-PET imaging. Eur. J. Nucl. Med. Mol. Imaging, 2010, 37, 250-259.
18. Vosjan, M.J.; Perk, L.R.; Visser, G.W.; Budde, M.; Jurek, P.; Kiefer, G.E.; van Dongen, G.A. Conjugation and radio labeling of monoclonal antibodies with zirconium-89 for PET imaging using the bifunctional chelate p-isothiocyanatobenzyl-desferrioxamine. Nat. Protoc., 2010, 5, 739-743.
19. Chakrabarti, M.C.; Le, N.; Paik, C.H.; De Graff, W.G.; Carrasquillo, J.A. Prevention of radiolysis of monoclonal antibody during labeling. J Nucl Med, 1996, 37, 1384-1388.
20. Meijs, W.E.; Haisma, H.J.; Klok, R.P.; van Gog, F.B.; Kievit, E.; Pinedo, H.M.; Herscheid, J.D. Zirconium-labeled monoclonal antibodies and their distribution in tumor-bearing nude mice. J. Nucl. Med., 1997, 38, 112-118.
21. Meijs, W.E.; Haisma, H.J.; Van der Schors, R.; Wijbrandts, R.; Van den Oever, K.; Klok, R.P.; Pinedo, H.M.; Herscheid, J.D. A facile method for the labeling of proteins with zirconium isotopes. Nucl. Med. Biol., 1996, 23, 439-448.
22. 89Zr-labeled monoclonal antibodies for ImmunoPET. Nucl. Med. Biol., 2010, 37, 289-297.
23. Cai, W.; Niu, G.; Chen, X. Multimodality imaging of the HERkinase axis in cancer. Eur. J. Nucl. Med. Mol. Imaging, 2008, 35, 186-208.
24. Niu, G.; Cai, W.; Chen, X. Molecular imaging of human epidermal growth factor receptor 2 (HER-2) expression. Front. Biosci., 2008, 13, 790-805.
25. Gross, M.E.; Shazer, R.L.; Agus, D.B. Targeting the HER-kinase axis in cancer. Semin. Oncol., 2004, 31, 9-20.
26. Dijkers, E.C.; Kosterink, J.G.; Rademaker, A.P.; Perk, L.R.; van Dongen, G.A.; Bart, J.; de Jong, J.R.; de Vries, E.G.; Lub-de Hooge, M.N. Development and characterization of clinical-grade 89Zr-trastuzumab for HER2/neu immunoPET imaging. J NuclMed, 2009, 50, 974-981.
27. Perik, P.J.; Lub-De Hooge, M.N.; Gietema, J.A.; van der Graaf, W.T.; de Korte, M.A.; Jonkman, S.; Kosterink, J.G.; van Veldhuisen, D.J.; Sleijfer, D.T.; Jager, P.L.; de Vries, E.G. Indium-111-labeled trastuzumab scintigraphy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J. Clin. Oncol., 2006, 24, 2276-2282.
28. 89Zr-trastuzumab PET visualises HER2 downregulation by the HSP90 inhibitor NVPAUY922 in a human tumour xenograft. Eur. J. Cancer, 2010, 46, 678-684.
29. Holland, J.P.; Caldas-Lopes, E.; Divilov, V.; Longo, V.A.; Taldone, T.; Zatorska, D.; Chiosis, G.; Lewis, J.S. Measuring the pharmacodynamic effects of a novel Hsp90 inhibitor on HER2/neu expression in mice using Zr-DFO-trastuzumab. PLoS One, 2010, 5, e8859.
30. 89Zrtrastuzumab and PET imaging of HER2-positive lesions in patients with metastatic breast cancer. Clin. Pharmacol. Ther., 2010, 87, 586-592.
31. Oude Munnink, T.H.; Dijkers, E.C.; Netters, S.J.; Lub-de Hooge, M.N.; Brouwers, A.H.; Haasjes, J.G.; Schroder, C.P.; de Vries, E.G. Trastuzumab pharmacokinetics influenced by extent human epidermal growth factor receptor 2-positive tumor load. J. Clin. Oncol., 2010, 28, e355-356.
32. Normanno, N.; De Luca, A.; Bianco, C.; Strizzi, L.; Mancino, M.; Maiello, M.R.; Carotenuto, A.; De Feo, G.; Caponigro, F.; Salomon, D.S. Epidermal growth factor receptor (EGFR) signaling in cancer. Gene, 2006, 366, 2-16.
33. Mitsudomi, T.; Yatabe, Y. Epidermal growth factor receptor in relation to tumor development: EGFR gene and cancer. FEBS J., 2010, 277, 301-308.
34. Herbst, R.S.; Shin, D.M. Monoclonal antibodies to target epidermal growth factor receptor-positive tumors: a new paradigm for cancer therapy. Cancer, 2002, 94, 1593-1611.
35. Goldstein, N.I.; Prewett, M.; Zuklys, K.; Rockwell, P.; Mendelsohn, J. Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Clin. Cancer Res., 1995, 1, 1311-1318.
36. 89Zr as a PET surrogate radioisotope for scouting biodistribution of the therapeutic radiometals 90Y and 177Lu in tumor-bearing nude mice after coupling to the internalizing antibody cetuximab. J. Nucl. Med., 2005, 46, 1898-1906.
37. Aerts, H.J.; Dubois, L.; Perk, L.; Vermaelen, P.; van Dongen, G.A.; Wouters, B.G.; Lambin, P. Disparity between in vivo EGFR expression and 89Zr-labeled cetuximab uptake assessed with PET. J. Nucl. Med., 2009, 50, 123-131.
38. Pines, G.; Kostler, W.J.; Yarden, Y. Oncogenic mutant forms of EGFR: lessons in signal transduction and targets for cancer therapy. FEBS Lett., 2010, 584, 2699-2706.
39. Yeh, H.H.; Ogawa, K.; Balatoni, J.; Mukhapadhyay, U.; Pal, A.; Gonzalez-Lepera, C.; Shavrin, A.; Soghomonyan, S.; Flores, L., 2nd; Young, D.; Volgin, A.Y.; Najjar, A.M.; Krasnykh, V.; Tong, W.; Alauddin, M.M.; Gelovani, J.G. Molecular imaging of active mutant L858R EGF receptor (EGFR) kinase-expressing nonsmall cell lung carcinomas using PET/CT. Proc. Natl. Acad. Sci. USA, 2011, Epub.
40. Olson, W.C.; Heston, W.D.; Rajasekaran, A.K. Clinical trials of cancer therapies targeting prostate-specific membrane antigen. Rev. Recent Clin. Trials, 2007, 2, 182-190.
41. Manyak, M.J. Indium-111 capromab pendetide in the management of recurrent prostate cancer. Expert Rev. Anticancer Ther., 2008, 8, 175-181.
42. 89Zr-DFO-J591 for immunoPET of prostate-specific membrane antigen expression in vivo. J. Nucl. Med., 2010, 51, 1293-1300.
43. Ruggiero, A.; Holland, J.P.; Lewis, J.S.; Grimm, J. Cerenkov luminescence imaging of medical isotopes. J. Nucl. Med., 2010, 51, 1123-1130.
44. Webb, D.S.; Shimizu, Y.; Van Seventer, G.A.; Shaw, S.; Gerrard, T.L. LFA-3, CD44, and CD45: physiologic triggers of human monocyte TNF and IL-1 release. Science, 1990, 249, 1295-1297.
45. Jacobson, K.; O'Dell, D.; Holifield, B.; Murphy, T.L.; August, J.T. Redistribution of a major cell surface glycoprotein during cell movement. J. Cell Biol., 1984, 99, 1613-1623.
46. Nestor, M.; Andersson, K.; Lundqvist, H. Characterization of 111In and 177Lu-labeled antibodies binding to CD44v6 using a novel automated radioimmunoassay. J. Mol. Recognit., 2008, 21, 179-183.
47. Mulder, J.W.; Kruyt, P.M.; Sewnath, M.; Oosting, J.; Seldenrijk, C.A.; Weidema, W.F.; Offerhaus, G.J.; Pals, S.T. Colorectal cancer prognosis and expression of exon-v6-containing CD44 proteins. Lancet, 1994, 344, 1470-1472.
48. Heider, K.H.; Kuthan, H.; Stehle, G.; Munzert, G. CD44v6: a target for antibody-based cancer therapy. Cancer Immunol. Immunother., 2004, 53, 567-579.
49. Colnot, D.R.; Quak, J.J.; Roos, J.C.; van Lingen, A.; Wilhelm, A.J.; van Kamp, G.J.; Huijgens, P.C.; Snow, G.B.; van Dongen, G.A. Phase I therapy study of 186Re-labeled chimeric monoclonalantibody U36 in patients with squamous cell carcinoma of the head and neck. J. Nucl. Med., 2000, 41, 1999-2010.
50. Colnot, D.R.; Ossenkoppele, G.J.; Roos, J.C.; Quak, J.J.; de Bree, R.; Borjesson, P.K.; Huijgens, P.C.; Snow, G.B.; van Dongen, G.A. Reinfusion of unprocessed, granulocyte colony-stimulating factorstimulated whole blood allows dose escalation of 186Relabeled chimeric monoclonal antibody U36 radioimmunotherapy in a phase I dose escalation study. Clin. Cancer Res., 2002, 8, 3401-3406.
51. de Bree, R.; Roos, J.C.; Plaizier, M.A.; Quak, J.J.; van Kamp, G.J.; den Hollander, W.; Snow, G.B.; van Dongen, G.A. Selection of monoclonal antibody E48 IgG or U36 IgG for adjuvant radioimmunotherapy in head and neck cancer patients. Br. J.Cancer, 1997, 75, 1049-1060.
52. Verel, I.; Visser, G.W.; Boerman, O.C.; van Eerd, J.E.; Finn, R.; Boellaard, R.; Vosjan, M.J.; Stigter-van Walsum, M.; Snow, G.B.; van Dongen, G.A. Long-lived positron emitters zirconium-89 and iodine-124 for scouting of therapeutic radioimmunoconjugates with PET. Cancer Biother. Radiopharm., 2003, 18, 655-661.
53. 89Zr-labeled chimeric monoclonal antibody U36 as used for immuno-PET in head and neck cancer patients. J. Nucl. Med., 2009, 50, 1828-1836.
54. Cai, W.; Chen, X. Multimodality imaging of vascular endothelial growth factor and vascular endothelial growth factor receptor expression. Front. Biosci., 2007, 12, 4267-4279.
55. Ellis, L.M.; Hicklin, D.J. VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat. Rev. Cancer, 2008, 8, 579-591.
56. Middleton, G.; Lapka, D.V. Bevacizumab (Avastin). Clin. J. Oncol. Nurs., 2004, 8, 666-669.
57. Nagengast, W.B.; de Vries, E.G.; Hospers, G.A.; Mulder, N.H.; de Jong, J.R.; Hollema, H.; Brouwers, A.H.; van Dongen, G.A.; Perk, L.R.; Lub-de Hooge, M.N. In vivo VEGF imaging with radiolabeled bevacizumab in a human ovarian tumor xenograft. J. Nucl. Med., 2007, 48, 1313-1319.
58. 89Zrbevacizumab PET of early antiangiogenic tumor response to treatment with HSP90 inhibitor NVP-AUY922. J. Nucl. Med., 2010, 51, 761-767.
59. Swietach, P.; Hulikova, A.; Vaughan-Jones, R.D.; Harris, A.L. New insights into the physiological role of carbonic anhydrase IX in tumour pH regulation. Oncogene, 2010, 29, 6509-6521.
60. 89Zr-labeled cG250-F(ab')2 in head and neck tumors. J. Nucl. Med., 2010, 51, 1076-1083.
61. Heskamp, S.; van Laarhoven, H.W.; Molkenboer-Kuenen, J.D.; Franssen, G.M.; Versleijen-Jonkers, Y.M.; Oyen, W.J.; van der Graaf, W.T.; Boerman, O.C. Immuno SPECT and immunoPET of IGF-1R expression with the radiolabeled antibody R1507 in a triple-negative breast cancer model. J. Nucl. Med., 2010, 51, 1565-1572.
62. Cai, W.; Chen, X. Nanoplatforms for targeted molecular imaging in living subjects. Small, 2007, 3, 1840-1854.
63. Hong, H.; Gao, T.; Cai, W. Molecular imaging with single-walledcarbon nanotubes. Nano Today, 2009, 4, 252-261.
64. Ruggiero, A.; Villa, C.H.; Holland, J.P.; Sprinkle, S.R.; May, C.; Lewis, J.S.; Scheinberg, D.A.; McDevitt, M.R. Imaging and treating tumor vasculature with targeted radiolabeled carbon nanotubes. Int. J. Nanomedicine, 2010, 5, 783-802.
65. 89Zr-RGD peptides. Mol. Imaging Biol., 2011, [Epub ahead of print].